Does Elafibranor have the effect of shrinking tumors?

Elafibranor is a selective peroxisome proliferator-activated receptor α/δ (PPARα/δ) agonist, which is mainly studied for the treatment of metabolic diseases such as non-alcoholic steatohepatitis (NASH). Its mechanism of action is mainly to regulate lipid metabolism and anti-inflammatory response, and improve liver fat deposition and inflammation. Although irafibratenol has shown positive effects in regulating metabolism and inflammation, there is currently insufficient clinical evidence that it has a direct tumor shrinking effect.

Regarding the anti-tumor potential of irafibratenol, some early studies and laboratory data suggest that PPAR agonists may play a regulatory role in certain tumor microenvironments, but these results are still in the preliminary stage and lack support from large-scale clinical trials. Therefore, irafibratenol is not currently approved for tumor treatment, nor is it used as a standard drug for tumor shrinkage.

Clinically, irafibratenol focuses more on improving liver metabolism abnormalities, delaying the progression of liver fibrosis and liver lesions, and reducing the risk of liver cancer. Its indirect protective effect may play a certain preventive role in tumor occurrence, but it cannot replace traditional anti-tumor treatments.
To sum up, irafibratenol has no clear tumor-shrinking effect at the current stage. If patients need tumor-related treatment, they should still follow the guidance of oncologists and adopt proven anti-cancer regimens. The main advantages of irafibratenol remain in the treatment of metabolic diseases and liver protection.
Reference: https://www.drugs.com